Trinity Biotech plc

TRIB Nasdaq SEC CIK 888721
Follow Trinity Biotech Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2024 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY14FY16FY18FY20FY22FY24
Show the numbers
YearRevenueNet income
FY24$61.6M−$31.8M
FY23$56.8M−$24M
FY22$62.5M−$41M
FY21$81.1M$875K
FY20$102M−$6.4M
FY19$90.4M−$28.9M
FY18$97M−$22.1M
FY17$99.1M−$40.3M
FY16$99.6M−$100.6M
FY15$100.2M$21.8M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−150%−100%−50%0%50%FY14FY16FY18FY20FY22FY24
Show the numbers
YearGross marginOperating marginNet margin
FY2434.8%−34.4%−51.6%
FY2334.2%−47.6%−42.3%
FY2227.6%−30.9%−65.6%
FY2141.2%4.9%1.1%
FY2047.6%0.1%−6.3%
FY1942.2%−26.7%−32%
FY1842.7%−20.8%−22.8%
FY1742.3%−38%−40.6%
FY1643.7%−40%−101%
FY1546.4%13.5%21.8%
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$20M−$10M$0$10M$20M$30MFY14FY16FY18FY20FY22FY24
Show the numbers
YearFree cash flow
FY24−$4.6M
FY23−$12.4M
FY22−$2M
FY21$11.4M
FY20$20.6M
FY19$3.3M
FY18−$299K
FY17$4.4M
FY16$6M
FY15$6.1M
FY14-
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$2.5M$5M$7.5M$10MFY14FY16FY18FY20FY22FY24
Show the numbers
YearDividendsBuybacks
FY24--
FY23--
FY22--
FY21--
FY20--
FY19--
FY18-$434K
FY17-$7.8M
FY16-$9.3M
FY15$5.1M-
FY14--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Trinity Biotech
  • Healthcare median
−150%−100%−50%0%50%FY14FY16FY18FY20FY22FY24
Show the numbers
YearTrinity BiotechHealthcare median
FY24−51.6%−47%
FY23−42.3%−58%
FY22−65.6%−80.4%
FY211.1%−71.9%
FY20−6.3%−62.2%
FY19−32%−46.3%
FY18−22.8%−49.6%
FY17−40.6%−45.9%
FY16−101%−36%
FY1521.8%−38.4%
FY14-−35.5%